Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Active, not recruiting Phase 3 Interventional

A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1)

ClinicalTrials.gov ID: NCT06799000

Public ClinicalTrials.gov record NCT06799000. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 21, 2026, 6:53 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-blind, Double-dummy, Placebo-controlled, Multicenter, Phase 3 Study Assessing the Efficacy, Safety, and Tolerability of 2 Doses of Remibrutinib Over a 68-week Treatment Period in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa. (RECHARGE-1)

Study identification

NCT ID
NCT06799000
Recruitment status
Active, not recruiting
Study type
Interventional
Phase
Phase 3
Lead sponsor
Novartis Pharmaceuticals
Industry
Enrollment
588 participants

Conditions and interventions

Interventions

  • Remibrutinib Dose A Drug
  • Remibrutinib Dose B Drug
  • Placebo 1 Drug
  • Placebo 2 Drug

Drug

Eligibility (public fields only)

Age range
12 Years to 100 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jan 30, 2025
Primary completion
May 16, 2027
Completion
Oct 3, 2027
Last update posted
May 21, 2026

2025 – 2027

United States locations

U.S. sites
36
U.S. states
21
U.S. cities
35
Facility City State ZIP Site status
Medical Dermatology Specialists Phoenix Arizona 85006
Johnson Dermatology Fort Smith Arkansas 72916
Arkansas Research Trials North Little Rock Arkansas 72117
Cheryl Effron MD Inc Anaheim California 92807
Physioseq Sacramento California 95826
Olive View UCLA Medical Center Sylmar California 91342
Clinical Trials Research Institute Thousand Oaks California 91320
Howard University College of Medicine Washington D.C. District of Columbia 20060
Florida Academic Centers Research and Education LLC Coral Gables Florida 33134
University of MiamiHealth System Miami Florida 33125
Ziaderm Research LLC North Miami Beach Florida 33162
Revival Research Institute LLC Evans Georgia 30809
Gwinnett Clinical Research Center Snellville Georgia 30078
Immunology-Rheumatology Research Suwanee Georgia 30024
Illinois Dermatology Institute Chicago Illinois 60602
Dawes Fretzin Clinical Rea Group Indianapolis Indiana 46256
Equity Medical LLC Bowling Green Kentucky 42104
Dermat. and Adv. Aesthetics Lake Charles Louisiana 70605
Michigan Center for Rsrch Company Clarkston Michigan 48346
Henry Ford Hospital Detroit Michigan 48202-2689
Revival Research Institute Troy Michigan 48084
University of Mississippi Med Ctr Jackson Mississippi 39216
Care Access Hoboken Hoboken New Jersey 07030
Forest Hills Dermatology Group New York New York 10003
Icahn School Of Med At Mount Sinai New York New York 10029
Skinsearch of Rochester Inc Rochester New York 14623
OnSite Clinical Solutions LLC Huntersville North Carolina 28078
Wake Forest Baptist Health Winston-Salem North Carolina 27104
Unity Clinical Research Oklahoma City Oklahoma 73118
Essential Medical Research Tulsa Oklahoma 74137
UP Medical Center H System Pittsburgh Pennsylvania 15213-3403
Medical University of South Carolina MUSC Charleston South Carolina 29425
Advanced Research Experts Nashville Tennessee 37211
Bellaire Dermatology Associates Bellaire Texas 77401
RFSA Dermatology San Antonio Texas 78213
Virginia Clinical Research Norfolk Virginia 23507

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 102 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT06799000, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted May 21, 2026 · Synced Jul 21, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06799000 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →